This study focuses on advancing personalized treatments for childhood acute lymphoblastic leukemia (ALL), particularly in "low-to-intermediate-risk" patients who respond poorly to early therapy and have higher risk of relapse. Building on a prior project, it aims to identify biomarkers to better distinguish true high-risk patients from lower-risk ones, allowing for more precise therapy adjustments. Researchers will explore targeted therapies for specific ALL types (ETV6::RUNX1 and TCF3::PBX1, and T-ALL) and assess the impact of dasatinib combined with new drugs in preclinical and early phase clinical settings. The project will utilize advanced AI, multi-omics, and high-throughput drug screens, with a broader goal of creating analysis methods applicable to other genetically based diseases.

2025

2028